Cover Image
市場調查報告書

口唇皰疹(口腔皰疹):開發中產品分析

Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 200959
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
口唇皰疹(口腔皰疹):開發中產品分析 Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2018
出版日期: 2018年05月08日 內容資訊: 英文 41 Pages
簡介

口腔皰疹是單純皰疹病毒所引起的嘴唇、口腔、齒齦感染症,也被稱為口唇皰疹。常見的症狀有喉嚨痛、發熱、腺體腫、吞嚥疼痛等。治療方法包含抗病毒藥物。

本報告提供口唇皰疹(口腔皰疹)的治療藥開發情形調查分析,提供開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

  • 調查範圍

簡介

口唇皰疹(口腔皰疹)概要

治療藥的開發

  • 開發中產品:概要
  • 各企業的開發平台
  • 大學/研究機關開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

正在開發的治療藥:各企業

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AiCuris GmbH & Co KG
  • Beech Tree Labs Inc
  • Foamix Pharmaceuticals Ltd
  • NanoViricides Inc
  • Onxeo SA
  • Shulov Innovative Science Ltd
  • Vironova AB

藥物簡介

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10415IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2018, provides an overview of the Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline landscape.

Oral herpes is an infection of the lips, mouth, or gums due to the herpes simplex virus. Oral herpes is also called herpes labialis. Symptoms include sore throat, fever, swollen glands and painful swallowing. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 4, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Herpes Labialis (Oral Herpes) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Herpes Labialis (Oral Herpes) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Herpes Labialis (Oral Herpes) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Labialis (Oral Herpes) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 4
  • Herpes Labialis (Oral Herpes) - Overview 5
  • Herpes Labialis (Oral Herpes) - Therapeutics Development 6
  • Herpes Labialis (Oral Herpes) - Therapeutics Assessment 12
  • Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development 20
  • Herpes Labialis (Oral Herpes) - Drug Profiles 22
  • Herpes Labialis (Oral Herpes) - Dormant Projects 34
  • Herpes Labialis (Oral Herpes) - Discontinued Products 35
  • Herpes Labialis (Oral Herpes) - Product Development Milestones 36
  • Appendix 39

List of Tables

  • Number of Products under Development for Herpes Labialis (Oral Herpes), H1 2018 7
  • Number of Products under Development by Companies, H1 2018 9
  • Number of Products under Development by Universities/Institutes, H1 2018 10
  • Products under Development by Companies, H1 2018 11
  • Products under Development by Universities/Institutes, H1 2018 12
  • Number of Products by Stage and Target, H1 2018 14
  • Number of Products by Stage and Mechanism of Action, H1 2018 16
  • Number of Products by Stage and Route of Administration, H1 2018 18
  • Number of Products by Stage and Molecule Type, H1 2018 20
  • Herpes Labialis (Oral Herpes) - Pipeline by AiCuris GmbH & Co KG, H1 2018 21
  • Herpes Labialis (Oral Herpes) - Pipeline by Beech Tree Labs Inc, H1 2018 21
  • Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides Inc, H1 2018 22
  • Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd, H1 2018 22
  • Herpes Labialis (Oral Herpes) - Dormant Projects, H1 2018 35
  • Herpes Labialis (Oral Herpes) - Discontinued Products, H1 2018 36

List of Figures

  • Number of Products under Development for Herpes Labialis (Oral Herpes), H1 2018 7
  • Number of Products under Development by Companies, H1 2018 8
  • Number of Products by Targets, H1 2018 13
  • Number of Products by Stage and Targets, H1 2018 13
  • Number of Products by Mechanism of Actions, H1 2018 15
  • Number of Products by Stage and Mechanism of Actions, H1 2018 15
  • Number of Products by Routes of Administration, H1 2018 17
  • Number of Products by Stage and Routes of Administration, H1 2018 17
  • Number of Products by Molecule Types, H1 2018 19
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018 19
Back to Top